Comparison of the effect of Cichorium intybus and N-acetylcysteine versus placebo on the reduction of liver complications of Fingolimod in patients with multiple sclerosis

Comparison of the effect of Cichorium intybus and N-acetylcysteine versus placebo on the reduction of liver complications of Fingolimod in patients with multiple sclerosis: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N410

Enrollment

Registered

2021-12-08

Start date

2021-12-31

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group 1:Tablet Fingolimod 0.5 mg once daily plus capsules containing Cichorium intybus extract 250 mg once daily for 4 months. Intervention 2: Intervention group 2:Tablet

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18 to 65 years; Multiple sclerosis; At least 3 weeks after receiving corticosteroids;

Exclusion criteria

Exclusion criteria: Pregnancy and lactation; History of tuberculosis, AIDS, hepatitis, diabetes, kidney failure, or hypertension

Design outcomes

Primary

Measure	Time frame
Serum levels of liver enzyme (ALT, AST, and bilirubin). Timepoint: 2 and 4 months after the intervention. Method of measurement: through laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDavood Sarmadi Khojasteh

Hamedan University of Medical Sciences

skhdavid@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026